Join the Pembrolizumab group to help and get support from people like you.
Pembrolizumab News
High Response to PD-1 Therapy Seen in Unresectable Desmoplastic Melanoma
TUESDAY, Aug. 19, 2025 – Patients with advanced desmoplastic melanoma have high response to single-agent anti-programmed death protein 1 (PD-1) therapy, according to a study published online Aug. 14...
Sustained Clinical Benefit Seen for Pembrolizumab + Axitinib in Advanced Renal Cancer
FRIDAY, Aug. 8, 2025 – For patients with advanced renal cell carcinoma (RCC), there is a sustained clinical benefit with pembrolizumab plus axitinib, according to a study published online Aug. 6 in...
An Artificial Sweetener May Hamper Immunotherapy Cancer Treatment
MONDAY, Aug. 4, 2025 — Findings from a study in mice suggest that using a common artificial sweetener, sucralose, could hamper certain immunotherapy treatments in cancer patients. However, for folks ...
Autoantibodies Influence Cancer Response To Immunotherapy, Study Says
MONDAY, July 28, 2025 — Cutting-edge immunotherapy drugs are incredibly effective against some cancers but barely put a dent in others – and researchers might now know why. Patients’ own autoa...
Adding Pembrolizumab to Standard Care Ups Event-Free Survival in Head, Neck Cancer
FRIDAY, June 27, 2025 – For patients with locally advanced head and neck squamous cell carcinoma (HNSCC), the addition of neoadjuvant and adjuvant pembrolizumab to standard care significantly...
FDA Approves Keytruda (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy
RAHWAY, N.J.--(BUSINESS WIRE) June 13, 2025 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1)
On March 19, 2025, the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the...
TACE + Lenvatinib, Pembrolizumab Tied to Improved Survival in Unresectable Liver Cancer
THURSDAY, Jan. 16, 2025 – For patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with the addition of lenvatinib and pembrolizumab is...
Adding Pembrolizumab Ups Survival in Stage III Undifferentiated Sarcoma
THURSDAY, Nov. 21, 2024 – For patients with stage III undifferentiated pleomorphic sarcoma or dedifferentiated or pleomorphic liposarcoma of the extremity and limb girdles, adding pembrolizumab to...
Science Reveals Why Cancer Immunotherapies Can Sometimes Harm the Heart
FRIDAY, Nov. 8, 2024 – Researchers think they’ve figured out why cancer treatments that harness a person’s immune system to fight a tumor can cause heart damage in rare instances. Further, what the...
Pembrolizumab Aids Survival With High-Risk Endometrial Cancer
MONDAY, Oct. 21, 2024 – Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study...
What You Need to Know After a Breast Cancer Diagnosis
SATURDAY, Oct. 5, 2024 – Breast cancer strikes 1 in 8 women in the United States, but being diagnosed with the disease can still make you feel alone. To cope with such devastating news, breast...
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
RAHWAY, N.J.--(BUSINESS WIRE) September 18, 2024 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved...
Adjuvant Pembrolizumab Improves Survival in Muscle-Invasive Urothelial Cancer
FRIDAY, Sept. 20, 2024 – Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk muscle-invasive urothelial carcinoma after radical...
Pembrolizumab + Chemo Beneficial for Early-Stage Triple-Negative Breast Cancer
THURSDAY, Sept. 19, 2024 – For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab yields a significant...
Further information
Related condition support groups
Breast Cancer, Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma, Hodgkin's Lymphoma, Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Renal Cell Carcinoma